Journal article
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
Abstract
BACKGROUND: Clinical trials (PALISADE [ARC003], ARTEMIS [ARC010]) proving efficacy and safety of peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) have used double-blind, placebo-controlled food challenges (DBPCFCs) to screen for eligibility and to evaluate efficacy. In routine clinical practice, individuals with peanut allergy do not always undergo food challenges to confirm diagnosis or determine candidacy for treatment.
OBJECTIVE: To …
Authors
Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernández-Rivas M; Hourihane JO; Krawiec M; Lieberman J
Journal
Annals of Allergy Asthma & Immunology, Vol. 129, No. 6, pp. 758–768.e4
Publisher
Elsevier
Publication Date
December 2022
DOI
10.1016/j.anai.2022.07.033
ISSN
1081-1206